Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

摘要: Hepatic fibrosis develops or progresses in 25 % of patients with autoimmune hepatitis despite corticosteroid therapy. Current management regimens lack reliable noninvasive methods to assess changes hepatic and interventions that disrupt fibrotic pathways. The goals this review are indicate promising monitor identify anti-fibrotic warrant evaluation. Laboratory can differentiate cirrhosis from non-cirrhosis, but their accuracy distinguishing histological stage is uncertain. Radiological include transient elastography, acoustic radiation force impulse imaging, magnetic resonance elastography. Methods based on ultrasonography comparable detecting advanced cirrhosis, performances may be compromised by inflammation obesity. Magnetic elastography has excellent performance parameters for all stages diverse liver diseases, uninfluenced inflammatory activity body habitus, been superior other radiological nonalcoholic fatty disease, emerge as the preferred instrument evaluate hepatitis. Promising site- organelle-specific agents, especially inhibitors nicotinamide adenine dinucleotide phosphate oxidases, transforming growth factor beta, inducible nitric oxide synthase, lysyl C–C chemokine receptors types 2 5. Autoimmune a pro-fibrotic propensity, methods, interventions, selective antioxidants collagen cross-linkage, strengthen current strategies.